Mass-Drug Administration to Reduce Malaria Transmission (MDATRANS)

This study has been completed.
Kilimanjaro Christian Medical Centre, Tanzania
London School of Hygiene and Tropical Medicine
Information provided by:
Radboud University Identifier:
First received: July 30, 2007
Last updated: August 12, 2008
Last verified: August 2008
In the 1950s, the WHO included mass drug administration (MDA) with antimalarial drugs as a tool for malaria control in 'exceptional conditions when conventional control strategies have failed'. Subsequently, MDA has received little attention until the introduction of artemisinin based combination therapy (ACT). The principle aim of MDA is to interrupt malaria transmission by clearing the population of sexual stage parasites, gametocytes, prior to the transmission season. Gametocytes are essential for propagation of the disease and elimination of gametocytes will result in a reduction in malaria transmission. As a consequence, a successful MDA will reduce the burden of disease in a population and is expected to have little influence on the development of protective immunity in areas of low transmission intensity. In Africa, only one large scale MDA study was conducted in the last 10 years. That study, conducted in The Gambia using sulphadoxine-pyrimethamine (SP) plus a single dose of artesunate (AS), failed to show a significant impact of MDA on malaria transmission. Possible reasons for this failure are the limited impact of the drug regimen (a single dose of AS) on malaria transmission, the incomplete coverage, the relatively high transmission intensity in the area and the migration of individuals between villages. Here, we propose to conduct an MDA study in an area of very low malaria transmission intensity in Tanzania. We use the highly active drug combination SP+AS (3 days) followed by a single dose of primaquine..

Condition Intervention
Malaria, Falciparum
Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg)
Drug: Artesunate (day 1,2,3: 4 mg/kg)
Drug: Primaquine-base (day 3: 0.75 mg/kg)
Drug: placebo tablets

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Prevention
Official Title: Mass-Drug Administration With a Gametocytocidal Drug Combination, a Model for a Transmission Blocking Vaccine

Resource links provided by NLM:

Further study details as provided by Radboud University:

Primary Outcome Measures:
  • malaria morbidity by active and passive case detection. [ Time Frame: during the entire study period ] [ Designated as safety issue: Yes ]
  • asexual parasite prevalence and density by microscopy, rapid diagnostic test and molecular QT-NASBA [ Time Frame: monthly during the entire study period ]
  • gametocyte prevalence and density by QT-NASBA and microscopy [ Time Frame: monthly during the entire study period ]
  • transmission intensity quantified by entomologic inoculation rate [ Time Frame: continuously during the study period ]
  • human infectious reservoir [ Time Frame: prior to the intervention and several months after the intervention ]

Secondary Outcome Measures:
  • asexual parasite and gametocyte density by microscopy and molecular QT-NASBA [ Time Frame: monthly during the study period ]
  • human immune responses to malaria antigens [ Time Frame: prior to the intervention and several months after the intervention ]
  • the prevalence of drug resistant parasite strains [ Time Frame: prior to the intervention and several months after the intervention ]
  • Possible side effects of intervention with primaquine, notably hemolysis [ Time Frame: one week after the intervention ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 6000
Study Start Date: February 2008
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Sulphadoxine-pyrimethemine (day 1) artesunate (day 1-3) primaquine (day 3)
Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg)
500mg S&25mg P/20 kg, 1 day, single dose
Drug: Artesunate (day 1,2,3: 4 mg/kg)
4 mg/kg, daily single dose over three days
Drug: Primaquine-base (day 3: 0.75 mg/kg)
single dose at 0.75 mg/kg on day 3
Placebo Comparator: 2
Placebo: lactose tablets (Albochin)
Drug: placebo tablets
3 days of lactose tablets (160mg) albochin

  Show Detailed Description


Ages Eligible for Study:   1 Year and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • permanent resident of the research area
  • age >1 years

Exclusion Criteria:

  • severe anemia
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00509015

Kilimanjaro Christian Medical Centre
Moshi, Tanzania
Sponsors and Collaborators
Radboud University
Kilimanjaro Christian Medical Centre, Tanzania
London School of Hygiene and Tropical Medicine
Principal Investigator: Seif Shekalaghe, MPH MD Kilimanjaro Christian Medical Centre
Study Chair: Robert Sauerwein, Prof MD PhD Radboud University
Study Director: Frank Mosha, PhD Kilimanjaro Christian Medical Centre
  More Information

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Seif Shekalaghe, Kilimanjaro Christian Medical Centre Identifier: NCT00509015     History of Changes
Other Study ID Numbers: APRIORI1/01
Study First Received: July 30, 2007
Last Updated: August 12, 2008
Health Authority: Tanzania: Food & Drug Administration

Keywords provided by Radboud University:
malaria transmission
mass drug administration
artemisinin-based combination therapy

Additional relevant MeSH terms:
Malaria, Falciparum
Parasitic Diseases
Protozoan Infections
Fanasil, pyrimethamine drug combination
Anti-Infective Agents
Anti-Infective Agents, Urinary
Antiparasitic Agents
Antiprotozoal Agents
Enzyme Inhibitors
Folic Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Renal Agents
Therapeutic Uses processed this record on December 01, 2015